Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.11 USD
Change Today +0.57 / 12.56%
Volume 3.1M
ARRY On Other Exchanges
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

array biopharma inc (ARRY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $8.59
52 Week Low
10/13/14 - $2.98
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ARRAY BIOPHARMA INC (ARRY)

array biopharma inc (ARRY) Related Bloomberg News

View More Bloomberg News

array biopharma inc (ARRY) Related Businessweek News

No Related Businessweek News Found

array biopharma inc (ARRY) Details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s drugs in Phase III clinical trials include Binimetinib and Encorafenib for the treatment of cancer. Its drug candidates in Phase II clinical trials include Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASC08/Danoprevir, a protease inhibitor for Hepatitis C virus; ASLAN001/ARRY-543, a pan-HER inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; and LY2606368, a chk-1 inhibitor for cancer. The company’s Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer; and ONT-380/ARRY-380, a HER2 inhibitor for breast cancer, as well as Phase I drug candidate includes GDC-0994, an ERK inhibitor for cancer and LOXO-101, a PanTrk inhibitor for cancer. Array BioPharma Inc. has collaboration agreements with Biogen Idec MA Inc.; Array and Celgene Corporation and Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc.; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

156 Employees
Last Reported Date: 08/21/15
Founded in 1998

array biopharma inc (ARRY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $558.3K
Chief Operating Officer
Total Annual Compensation: $376.5K
Chief Medical Officer
Total Annual Compensation: $430.2K
Vice President, General Counsel and Secretary
Total Annual Compensation: $383.7K
Compensation as of Fiscal Year 2015.

array biopharma inc (ARRY) Key Developments

Array BioPharma Inc. Announces Clinical Results on Binimetinib and Encorafenib in Melanoma

Array BioPharma Inc. announced that clinical trial results from company's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's (ESMO) annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of bini metinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients. BRAF-mutant Melanoma Preliminary Results: LOGIC2 is an ongoing 140-patient, two-part study designed to explore the safety and activity of novel triplet combinations in BRAF-mutant melanoma. In part 1, patients are treated with the combination of binimetinib and encorafenib until disease progression. Based on the results of molecular profiling at that time, each patient is assigned to one of four arms containing a triplet combination of binimetinib, encorafenib and a third targeted therapy. Results from part 1 of the study are reported separately for patients who have previously received a BRAF and/or MEK inhibitor versus those who were initially naive to BRAF and MEK inhibitor treatment. In part 1, patients are treated with binimetinib 45 mg twice daily (BID) and encorafenib 450 mg once daily (QD), the same doses evaluated in the ongoing Phase 3 COLUMBUS trial. In the BRAF/MEK-naive group (n=40), the interim overall response rate (confirmed and unconfirmed complete response or partial response) was 68%, with a 6-month progression-free survival estimate of 79%. Of note, 96% of patients in this group continued to receive study treatment as of the data cutoff. Preliminary data from all patients in the study (n=89) also indicate that the combination of binimetinib and encorafenib showed good tolerability with a 12% incidence of pyrexia and little to no rash or photosensitivity. These results indicate that the combination of binimetinib and encorafenib show encouraging clinical activity and an emerging differentiated tolerability profile relative to other MEK/BRAF inhibitor combinations. NRAS-mutant Melanoma Interim Results: A Phase 1b/2 study of binimetinib in combination with ribociclib showed promising preliminary antitumor activity in NRAS-mutant melanoma patients. Results were shared from 45 patients enrolled in the dose escalation portion of the study, which included two dosing schedules (28-day or 21-day cycles). For the 28-day dosing schedule, patients received continuous twice daily dosing of binimetinib while receiving ribociclib for 21 days per 28 day cycle. For the 21-day schedule, both agents were delivered for 14 days of a 21 day cycle. For patients receiving the combination on a 28-day cycle (n=22), the Objective Response Rate (ORR, confirmed and unconfirmed complete or partial responses) was 41%, the Disease Control Rate (DCR, confirmed and unconfirmed complete or partial responses and stable disease) was 82% with a median Progression Free Survival (mPFS) of 6.7 months. Furthermore, the ORR was 56% (n=9) for patients receiving dose level 1 of the 28-day schedule consisting of binimetinib 45 mg BID and the lowest dose of ribociclib (200 mg QD), indicating that robust activity can be achieved with this dose and schedule. Common treatment-related adverse events included elevated creatine phosphokinase (CPK), skin and gastrointestinal events. Investigation of an alternative 21-day schedule is ongoing. Melanoma is the fifth most common cancer among men and the seventh most common cancer among women in the United States, with almost 74,000 new cases and nearly 10,000 deaths from the disease projected in 2015. BRAF and NRAS mutations occur in approximately 40% to 60% and 15% to 20%, respectively, of patients with melanoma. When melanoma is diagnosed early, it is generally a curable disease. However, when it spreads to other parts of the body, it is the deadliest and most aggressive form of skin cancer. Raf and MEK are key protein kinases in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Inappropriate activation of this pathway has been shown to occur in many cancers, such as non-small cell lung cancer, melanoma, colorectal and thyroid cancers. Binimetinib is a small molecule MEK inhibitor and encorafenib is a small molecule BRAF inhibitor, both of which target key enzymes in this pathway. Three Phase 3 trials in advanced cancer patients continue to advance: NRAS-mutant melanoma (NEMO, with binimetinib), low-grade serous ovarian cancer (MILO, with binimetinib) and BRAF-mutant melanoma (COLUMBUS, with binimetinib and encorafenib). The NEMO and COLUMBUS Part 1 studies completed enrollment in April 2015. NRAS-mutant melanoma represents the first potential indication for binimetinib, with a projected regulatory filing estimated in the first half of 2016. Array also projects a regulatory filing of binimetinib in combination with encorafenib in BRAF melanoma in 2016.

Array BioPharma Inc. - Special Call

To discuss preliminary results from two melanoma trials and a colorectal cancer trial

Array BioPharma Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 02:05 PM

Array BioPharma Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 02:05 PM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Ron Squarer, Chief Executive Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARRY:US $5.11 USD +0.57

ARRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $1.98 USD +0.17
CTI BioPharma Corp $1.51 USD +0.05
Cytokinetics Inc $6.96 USD +0.11
Evotec AG €3.97 EUR -0.017
Progenics Pharmaceuticals Inc $5.90 USD +0.53
View Industry Companies

Industry Analysis


Industry Average

Valuation ARRY Industry Range
Price/Earnings 77.3x
Price/Sales 13.9x
Price/Book 17.0x
Price/Cash Flow 77.6x
TEV/Sales 8.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARRAY BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at